BioCorRx (BICX) Cash & Equivalents (2010 - 2026)
BioCorRx's Cash & Equivalents came in at $21,237 for Q2 2026, down 81.0% from $111,872 a year earlier and down 90.0% from the prior quarter.
Powered by 
Analysis
BioCorRx (BICX) Cash & Equivalents (2010 - 2026) Analysis & Trends
At the end of FY2025, BioCorRx's Cash & Equivalents was $139,360, up 58.3% from FY2024.
- Cash & Equivalents carries a five-year compound annual growth rate of -25.1% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $88,033 in FY2024 (+35.0%), $65,222 in FY2023 (-4.9%), $68,615 in FY2022 (-20.1%) and $85,838 in FY2021 (-85.5%).
- The Q2 2026 figure represents the lowest quarterly Cash & Equivalents since Q3 2024.
- Year-over-year, Cash & Equivalents increased in three of the last six quarters, with growth averaging 102.3%.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q1 2026 (growth of 777.8%), and the weakest in Q3 2024 (a decline of 99.9%).
- Business Quant data shows BICX's Cash & Equivalents at $211,911 (Q1 2026), $139,360 (Q4 2025) and $287,688 (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | BioCorRx | 3.63 Mn | 2.97 Mn | - | 21,237.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21,237.00 |
| Mar 31, 2026 | 211,911.00 |
| Dec 31, 2025 | 139,360.00 |
| Sep 30, 2025 | 287,688.00 |
| Jun 30, 2025 | 111,872.00 |
| Mar 31, 2025 | 24,142.00 |
| Dec 31, 2024 | 88,033.00 |
| Sep 30, 2024 | 90.00 |
| Jun 30, 2024 | 8,365.00 |
| Mar 31, 2024 | 101,080.00 |
| Dec 31, 2023 | 65,222.00 |
| Sep 30, 2023 | 156,409.00 |
| Jun 30, 2023 | 197,304.00 |
| Mar 31, 2023 | 203,687.00 |
| Dec 31, 2022 | 68,615.00 |
| Sep 30, 2022 | 63,529.00 |
| Jun 30, 2022 | 111,461.00 |
| Mar 31, 2022 | 213,166.00 |
| Dec 31, 2021 | 85,838.00 |
| Sep 30, 2021 | 745,457.00 |
API Access
BioCorRx Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=BICX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "BICX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=BICX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();